FindTrial
Sign In

To compare two different doses of intravenous Dexmedetomidine (0.5µg/kg vs 1.0µg/kg) in attenuating hemodynamic response to direct laryngoscopy and endotracheal intubation.

comparison of Intravenous 0.5µg per kg Vs 1µg per kg of Dexmedetomidine for effect on hemodynamic variability during direct laryngoscopy & endotracheal intubation in elective surgeries under General Anaesthesia: A Randomized Double Blind Interventional Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/037014
Enrollment
76
Registered
2021-09-30
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: Injection Dexmedetomidine 0.5 microgram: Dexmedetomidine infusion 0.5 microgram per kg in 20 ml of normal saline over 10 minutes via infusion pump Control Intervention1: Injection Dexme

Sponsors

Sawai Man Singh Medical College And Attached Hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient undergoing elective surgery under general anaesthesia. ASA Class I and Class II. Age group between 20-50 years Patients of either sex Patients who give informed written consent.

Exclusion criteria

Exclusion criteria: Patients with anticipated difficult airway or those in whom laryngoscopy time exceeded 20 seconds. Patients with H/O hypertension or on any antihypertensive medicine. Patients with physical dependence on narcotics history of drug or alcohol abuse. Known drug allergy to dexmedetomidine.

Design outcomes

Primary

MeasureTime frame
To assess and compare the effect of two different doses of intravenous Dexmedetomidine on HR, SBP, DBP, MAP at various time intervals (from baseline to 5 and 10 minutes after infusion and 1,2,3,5,10 minute post intubation). Timepoint: To assess and compare the effect of two different doses of intravenous Dexmedetomidine on HR, SBP, DBP, MAP at various time intervals (from baseline to 5 and 10 minutes after infusion and 1,2,3,5,10 minute post intubation).—

Secondary

MeasureTime frame
1. To determine the proportion of cases who experienced side effects in first 24 hours post induction period in both groups. 2. To observe the effect on required Induction dose of Thiopentone .Timepoint: 24 hours—

Countries

India

Contacts

Public ContactDr sachin Kumar Bansal

SMS MEDICAL COLLEGE JAIPUR

drneelu13@gmail.com9782480455

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026